Gapping up
In reaction to strong earnings/guidance: RHT +13.84%, FINL +4.63%, WAG +1.83%
M&A news: JNY +4.39%(To be acquired by Sycamore Partners for $15 per share in cash); GENT +2.4% (To be acquired by Jazz Pharmaceuticals for $57 per share in cash tender offer)
Other news: AMRN +15.09%( receives FDA notification that action on ANCHOR sNDA review will be delayed), APRI +7.4% (announced national phase approval for erectile dysfunction cream - Vitaros in France), TRAK +6.7% (announced agreement to acquire Dealer.com for 8.7 mln shares of common stock and $620 mln in cash), CIM +2.56% (Announced special dividend of $0.20 per share),BCRX +1.44% (files peramivir NDA for the treatment of influenza ), RAD +0.77% (along with WAG)
Analyst comments: CCL +3.68% (upgraded to Outperform from Neutral at Credit Suisse; raises tgt to $43), ARRS +0.78% (upgraded to Buy from Hold at Jefferies; tgt $30)
M&A news: JNY +4.39%(To be acquired by Sycamore Partners for $15 per share in cash); GENT +2.4% (To be acquired by Jazz Pharmaceuticals for $57 per share in cash tender offer)
Other news: AMRN +15.09%( receives FDA notification that action on ANCHOR sNDA review will be delayed), APRI +7.4% (announced national phase approval for erectile dysfunction cream - Vitaros in France), TRAK +6.7% (announced agreement to acquire Dealer.com for 8.7 mln shares of common stock and $620 mln in cash), CIM +2.56% (Announced special dividend of $0.20 per share),BCRX +1.44% (files peramivir NDA for the treatment of influenza ), RAD +0.77% (along with WAG)
Analyst comments: CCL +3.68% (upgraded to Outperform from Neutral at Credit Suisse; raises tgt to $43), ARRS +0.78% (upgraded to Buy from Hold at Jefferies; tgt $30)